Trial · NCT03339921
Botulinum for Chronic Exertional Compartment Syndrome
NCT03339921, Phase 2, Phase 3, Terminated, 375th Medical Group, Scott Air Force Base; results first posted 2024-03-05
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Botulinum for Chronic Exertional Compartment Syndrome. Trials, record NCT03339921. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03339921
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Botulinum for Chronic Exertional Compartment Syndrome
- NCT number
- NCT03339921
- Status
- Terminated
- Phases
- Phase 2, Phase 3
- Enrollment
- 3 participants, actual
- Lead sponsor
- 375th Medical Group, Scott Air Force Base
- Conditions
- Chronic Exertional Compartment Syndrome
- Interventions
- Botulinum toxin injections for chronic compartment syndrome, surgical fasciotomy for chronic compartment syndrome
- First posted
- 2017-11-13
- Last updated
- 2024-03-05
- Results first posted
- 2024-03-05
- Limitations and caveats
- This study was terminated because it is unworkable.
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Lower Extremity Functional Index | 6 months | The Lower Extremity Functional Index measures the functional impairment of a patient with a lower extremity disorder. It can be used to monitor the patient over time and to evaluate the effectiveness of an intervention. Score ranges from 0 to 80. Lower scores indicate more functional impairment. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Lower Extremity Functional Index | 6 months | No subjects were analyzed by a biostatistician. This study was terminated because it is unworkable. Raw data are reported. | score on a scale | MEAN |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Lower Extremity Functional Index | Botulinum Toxin Injections | Lower Extremity Functional Scale Immediately Post Treatment | 57 | Full Range 48 to 67 | score on a scale |
| Lower Extremity Functional Index | Botulinum Toxin Injections | Lower Extremity Functional Scale Month 1 | 60 | Full Range 34 to 78 | score on a scale |
| Lower Extremity Functional Index | Botulinum Toxin Injections | Lower Extremity Functional Scale Month 2 | 62 | Full Range 52 to 67 | score on a scale |
| Lower Extremity Functional Index | Botulinum Toxin Injections | Lower Extremity Functional Scale Month 6 | 55 | Full Range 45 to 68 | score on a scale |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Botulinum Toxin Injections | 3 | |
| Overall Study | STARTED | Surgical Fasciotomy | 0 | |
| Overall Study | COMPLETED | Botulinum Toxin Injections | 3 | |
| Overall Study | COMPLETED | Surgical Fasciotomy | 0 | |
| Overall Study | NOT COMPLETED | Botulinum Toxin Injections | 0 | |
| Overall Study | NOT COMPLETED | Surgical Fasciotomy | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Botulinum Toxin Injections | 0 | 3 |
| Total, all-cause mortality | Surgical Fasciotomy | 0 | 0 |
| Total, other adverse events | Botulinum Toxin Injections | 0 | 3 |
| Total, other adverse events | Surgical Fasciotomy | 0 | 0 |
| Total, serious adverse events | Botulinum Toxin Injections | 0 | 3 |
| Total, serious adverse events | Surgical Fasciotomy | 0 | 0 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03339921
GET https://conductscience.org/api/trials/v1/NCT03339921/registered